Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
By J. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, J. Woyach, S. Jaglowski, Y. Zhong, J. Hessler, Ta-Ming Liu, B. Chang, K. Larkin and 19 more. Blood, 2013
753 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/1e4cf1c0fa57fbd05877350a198429c8974da31b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Pathology and Forensic Medicine
Citations in the corpus
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…injection of a TLR9 agonist Sagiv-Barfi et al., 2015 immortalized human T lymphocytes robustly inhibits TH2 polarization ITK-dependent effect Dubovsky et al., 2013 Imatinib CML promotes the expansion of circulating NK cells persisting as long as 3 years after discontinuation Mizoguchi et…”
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, neutral): “Median age, years (range) 71 (65-84) 64 (37-82) 68 (37-84)”
- Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “Paradoxically, inhibiting ITK in T cells may be efficacious in cancer, as this may enhance Th1-skewing of CD4 T-cells and thereby improved memory formation and functionality of CD8 T-cells, potentially leading to improved anti-tumor immunity [243, 247].”